‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
Global - Oceania
Archived
•
October 22, 2026
•
Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised wayGet our new political email, free app or daily news podcastA personalised mRNA-based melanoma vaccine significantly reduces the risk of cancer recurrence or death within two years, new clinical trial results show.The vaccine, intismeran, is custom-made to target genetic mutations unique to an individual’s melanoma. It is the first individualised cancer vaccine to show positive results in a phase III clinical trial. Continue reading...
Source: Guardian Australia | https://www.theguardian.com/australia-news/rss - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



